within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB06_Darolutamide;

model Darolutamide
  extends Pharmacolibrary.Drugs.ATC.L.L02BB06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L02BB06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Darolutamide is a nonsteroidal androgen receptor antagonist used to treat non-metastatic castration-resistant prostate cancer. It is an approved oral medication and is currently used in clinical settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult male patients with non-metastatic castration-resistant prostate cancer following oral administration of darolutamide 600 mg twice daily under fed condition.</p><h4>References</h4><ol><li><p>Zurth, C, et al., &amp; Gieschen, H (2019). Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. <i>European journal of drug metabolism and pharmacokinetics</i> 44(6) 747–759. DOI:<a href=&quot;https://doi.org/10.1007/s13318-019-00577-5&quot;>10.1007/s13318-019-00577-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31571146/&quot;>https://pubmed.ncbi.nlm.nih.gov/31571146</a></p></li><li><p>Nykänen, P, et al., &amp; Koskinen, M (2021). Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020). <i>Drug metabolism letters</i> 14(1) 9–16. DOI:<a href=&quot;https://doi.org/10.2174/1872312814666201112121129&quot;>10.2174/1872312814666201112121129</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33183216/&quot;>https://pubmed.ncbi.nlm.nih.gov/33183216</a></p></li><li><p>Zurth, C, et al., &amp; Koskinen, M (2022). Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. <i>Clinical pharmacokinetics</i> 61(4) 565–575. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01078-y&quot;>10.1007/s40262-021-01078-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34866168/&quot;>https://pubmed.ncbi.nlm.nih.gov/34866168</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Darolutamide;
